A study of pembrolizumab in advanced melanoma (ADAPTeM)
Cancer type:
Status:
Phase:
This study looked at taking tissue samples to check how pembrolizumab was working at certain time points during treatment. The study is for people whose cancer has spread to another part of the body (advanced melanoma).
More about this trial
Pembrolizumab is a type of immunotherapy. This type of treatment stimulates the body’s immune system to fight cancer cells.
It targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
In this study, researchers planned to take tissue samples (
) of the areas where the melanoma has spread to. Looking at how cancer cells respond to treatment can help doctors find out which people benefit most.
The aims of the study were to find out:
- how pembrolizumab affects cancer cells at various time points
- if it is possible and safe to take a number of biopsies during treatment
Summary of results
There aren't any results for this study. This is because the trial closed early due to poor recruitment.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr James Larkin
Supported by
Cancer Research UK London Research Institute
Merck Sharp Dohme
The Royal Marsden NHS Foundation Trust
University College London Cancer Institute
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
